UK markets open in 4 hours 34 minutes

Evgen Pharma plc (EVG.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
0.77500.0000 (0.00%)
At close: 02:22PM BST

Evgen Pharma plc

Alderley Park, Block 24
Suite 24G13 Congleton Road
Nether Alderley SK10 4TG
United Kingdom
44 1625 315 090

Full-time employees10

Key executives

NameTitlePayExercisedYear born
Dr. Huw Jones BSc, Ph.D.CEO & Executive Director304.73kN/A1959
Mr. Toni HaenninenCFO & DirectorN/AN/A1977
Dr. Helen KuhlmanChief Business OfficerN/AN/AN/A
Dr. Glen Clack FFPM, M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Corporate governance

Evgen Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.